From Princeton University: An interdisciplinary team of researchers, including those from Princeton University, sequenced a region of chromosome 6 in dogs and found multiple sections of canine DNA that were associated with differences in social behavior. In many cases, unique genetic insertions called transposons on the Williams-Beuren syndrome critical region (WBSCR) were strongly associated with the tendency to seek out humans for physical contact, assistance and information.
In contrast, in humans, it is the deletion of genes from the counterpart of this region on the human genome, rather than insertions, that causes Williams-Beuren syndrome, a congenital disorder characterized by hyper-social traits such as exceptional gregariousness.
Closer to a Cure: Zander Therapeutics, Inc. Reports Research Demonstrating Ex-Vivo Immune Suppression of IL-17a and IL-2 in Dogs With Novel NR2F6 Activators
Zander Therapeutics, Inc., a subsidiary of Entest BioMedical Inc. (OTCPINK: ENTB) reported that researchers for Regen BioPharma Inc. have identified what the company believes to be a strong activator for modulating checkpoint NR2F6. This is significant to Zander Therapeutics for two reasons; Zander is the exclusive licensee of Regen BioPharma's technology for veterinary applications and the study involved small samples of dog blood used in ex vivo studies.
Zander Therapeutics Inc. Announces Brian Devine, Former Chairman of PETCO, to Helm its Business Advisory Board
Brian Devine, retired Chairman of PETCO, a leading pet specialty retailer, has agreed to serve as Chairman of the Business Advisory Board for Zander Therapeutics, Inc., a veterinary life sciences company and subsidiary of Entest BioMedical Inc. (OTCPINK: ENTB). "Mr. Devine's vast expertise in the animal health market, as well as his legacy of support for pet health, are an ideal match for our company," says David Koos, PhD, Chairman and CEO of Zander. "He understands the business networks we navigate, and we are honored to have our company associated with such an accomplished individual in the pet care industry."
Entest BioMedical's Subsidiary Zander Therapeutics, Inc., Reports Its Series A Compounds Suppressed the Production of Multiple Cytokines Known to be Involved in Inflammation With No Toxicity In Canine Studies
Company sees results demonstrating a major step forward in its small molecule anti-inflammatory drug development for veterinary use. Entest BioMedical Inc.'s (OTC-PINK: ENTB) subsidiary, Zander Therapeutics, Inc. has tested compounds that act on human cells in suppressing the immune system in a small amount of dog blood. The results indicate that one of the compounds, termed Series A, suppressed the production of multiple cytokines known to be involved in inflammation by activating checkpoint NR2F6. These include IL-17a, IL-1, IL-2, TNF-α and IFN-ɣ production from activated peripheral blood mononuclear cells in a non-toxic manner.
Entest BioMedical's Subsidiary Zander Therapeutics, Inc. Reports on Preliminary Canine Experiments Testing New Anti-Inflammatory Drug Compounds
Entest BioMedical Inc.'s (PINK: ENTB) subsidiary, Zander Therapeutics Inc. ,reported that initial data from its canine study suggest that compounds currently being tested ex vivo show promise as small molecule anti-inflammatory treatments in canines. The Company is in the process of developing anti-cancer and anti-inflammatory drugs for the Canine, Feline and Equine markets. David Koos, CEO of both Entest BioMedical and Zander, stated "Finding that compounds being developed by Regen BioPharma, Inc. for modulating NR2F6 in humans appear to modulate NR2F6 in dogs is an extremely exciting development. There can be a direct crossover effect in drug development."
Entest BioMedical, Inc. Settles $841,531 of Principal Indebtedness Through the Issuance of Equity Securities
Company views debt settlement as a positive step in cleaning up balance sheet.
Entest BioMedical Inc. (PINK: ENTB) announced today that it has satisfied $841,531 of Notes Payable as well as $83,000 of accrued expenses through the issuance of the Company's non-voting convertible preferred stock to the creditors. The terms of the settlement are disclosed in a form 8K dated May 30, 2017 filed by the Company with the United States Securities and Exchange Commission and publicly available through the SEC's EDGAR system.
Entest BioMedical's Chairman Discusses its Subsidiary, Zander Therapeutics, Inc.'s Progress With Small Molecule Immunotherapies for Treating Cancer and Arthritis in Dogs
Entest BioMedical Inc.'s (OTCPINK: ENTB) Chairman and CEO David Koos discussed current and anticipated developments for the company's subsidiary, Zander Therapeutics Inc. Specifically, Zander Therapeutics is moving forward in the area of immunotherapy delivered through small molecule treatments. The company is the exclusive licensee for veterinary applications of Regen BioPharma's intellectual property for modulating the checkpoint NR2F6 to treat cancer and arthritis.
Entest BioMedical's Subsidiary, Zander Therapeutics, Inc., Initiates Ex Vivo Studies on Modulating NR2F6 in Canines
Entest BioMedical Inc.'s (ENTB) subsidiary, Zander Therapeutics, Inc., has contracted with ChemDiv, Inc., an internationally recognized contract research organization, to test certain NR2F6 modulators licensed to Zander Therapeutics by Regen BioPharma in a cellular system. Specifically, the experiments will determine whether these compounds can suppress or activate the canine immune system. These experiments are performed using a small amount of blood that is drawn from a donor animal. The drugs to be tested are those that have been identified as having a similar cellular effect in human blood.
Entest BioMedical Inc.'s Subsidiary Zander Therapeutics Announces Appointment of Dr. Thomas Donnelly to Serve as Senior Veterinary Advisor
Dr. Donnelly is an Internationally Recognized Animal Researcher, who the Company Believes Will Play an Important Role in the Development of Zander's NR2F6 Small Molecule Drug Development Program for Veterinary Applications in Treating Canine Cancer and Arthritis in Animals.
Entest BioMedical Inc.'s Zander Therapeutics Unit Announces Publication of Canine Cellular Immunotherapy Patent Application for Treating Cancer in Dogs
Entest BioMedical Inc.'s (OTCPINK: ENTB) wholly owned subsidiary, Zander Therapeutics Inc., announced today publication by the United States Patent and Trademark Office of a Utility Patent application entitled "Canine Autologous Immunotherapy using Dendritic Cell Induced Cancer Killing Immunocytes". This patent application, which has a priority date of July 2015 and is assigned to Zander Therapeutics, covers the generation of a new type of cell from dog blood which possesses ability to kill tumor cells.
Entest BioMedical Inc.'s Subsidiary Zander Therapeutics Makes Key Additions to Management Team as the Company Prepares to Move Forward in the $63 Billion Veterinary / Pet Market Niche
Zander Prepares to Move Forward With Development of its Small Molecule Therapies for Treating Animals With Cancer and Autoimmune Disorders Which Include Arthritis
Entest BioMedical Inc.'s (OTCPINK: ENTB) Zander Therapeutics subsidiary has added Harry Lander, PhD, MBA as its President and Chief Scientific Officer and Todd S. Caven as its Chief Financial Officer. Thomas Ichim, PhD will assist the company as its Senior Scientific Consultant and Debbie Dorsee will serve as Director of Business Development.
Zander Therapeutics Inc. is focused on the rapidly growing veterinary medicine market niche. In 2016, the U.S. pet market was estimated to be $62.75 billion dollars in size, which is up from $38.5 billion in 2006 and $48.53 billion in 2010. Out of $62.75 billion, $16 billion was spent on veterinary care alone.
Entest BioMedical's Zander Therapeutics Unit Files Patent Application for its Proprietary NR2F6 Target to Treat Exercise-Induced Pulmonary Hypertension
Filing supports intent to treat a serious ailment specific to racehorses
SAN DIEGO -- January 10, 2016 -- Entest BioMedical Inc. (OTCPINK: ENTB) announced that its Zander Therapeutics unit has filed of a patent application covering use of newly-identified activators of nuclear receptor NR2F2 for the treatment of a racehorse-specific condition termed “Exercise Induced Pulmonary Hemorrhage (EIPH).”
Entest BioMedical Inc.'s Subsidiary Zander Therapeutics Files Patent Application on its Proprietary NR2F6 Target for the Treatment of Exercise Induced Pulmonary Hypertension Frequently Found in Thoroughbred Horses
Entest BioMedical Inc. (OTCPINK: ENTB) announced today that its subsidiary, Zander Therapeutics, Inc., has filed of a United States patent application covering use of newly identified activators of NR2F6 for the treatment of a Racehorse-specific condition termed "Exercise Induced Pulmonary Hemorrhage (EIPH)." This condition is characterized by the presence of blood in the airways of a horse's lung during exercise. According to a recent study, 60 percent of Thoroughbred racehorses have evidence of blood in their trachea, with 20 percent having moderate to severe EIPH (grades 2-4) after any given race. Horses with a grade 2 score or higher have significantly decreased performance.
Entest Biomedical, Inc. Chairman David Koos Discusses Zander Therapeutics Subsidiary And Future Plans For The Company Moving Into 2017
Entest BioMedical, Inc. (PINKS: ENTB) Chairman & CEO David Koos discussed the Company's plans for 2017 including plans for Zander Therapeutics, Inc., the Company's subsidiary.
Entest BioMedical's Zander Therapeutics Unit Files Composition of Matter Patent on NR2F6 Modulating Small Molecules in Canine and Feline Applications
A Potential Treatment for Cancer and Arthritis in Animals
Entest BioMedical's (OTCPINK: ENTB) subsidiary Zander Therapeutics, Inc. announced the filing of a patent application covering composition of matter and methods of use related to molecules identified in their small molecule program that activate and inhibit NR2F6 ('Small Molecule Modulators of NR2F6 Activity for Animals').
Entest BioMedical's Zander Therapeutics Unit Files Patent Application on Ex Vivo Activated Autologous Immune Cells
Entest BioMedical Inc.'s (OTC: ENTBD) Zander Therapeutics unit announced today its personalized canine cancer immune therapy platform and proof-of-concept experimental data. The data on which this provisional patent was based came from previous research conducted by Thomas Ichim, PhD, a scientific consultant to Zander. On July 31, 2015, Zander filed a provisional patent application with the United States Patent Office (USPTO) on intellectual property in the veterinary oncology space.
Entest BioMedical Inc.'s Zander Therapeutics Unit: Initial Focus is Small Molecule and Cancer Stem Targeting for Veterinary Oncology
Zander Therapeutics, a subsidiary of Entest BioMedical Inc. (OTC: ENTBD), announced today its canine cancer therapeutics and feline leukemia platforms. These platforms will focus on adopting cutting edge technologies such as immune-oncology, small molecule, gene silencing and cancer stem cell targeting for the treatment of cancer in dogs and leukemia in cats.
Zander Therapeutics :: Specializing in cutting edge therapies for animals
Founded in 2015 as a biotechnology company focused on veterinary medicine, specifically small molecule treatments for veterinary cancers, autoimmune diseases such as arthritis and other immunotherapies for specialty niche treatments. Zander is wholly owned by Entest BioMedical Inc. a fully reporting and trades publicly under the symbol: ENTB Focused on immuno-oncology, stem cell/cancer stem cell, gene silencing.
Copyright Zander Therapeutics, Inc. 2017